JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Samuk Taukinos
Country: Senegal
Language: English (Spanish)
Genre: Business
Published (Last): 7 November 2012
Pages: 79
PDF File Size: 9.60 Mb
ePub File Size: 16.56 Mb
ISBN: 861-7-76788-795-8
Downloads: 81118
Price: Free* [*Free Regsitration Required]
Uploader: Totilar

Rosuvastatin in renal disease Advanced kidney disease is associated with high cardiovascular morbidity and death. Subsequent meta-analysis of clinical trials and post marketing experience have consistently shown that rosuvastatin juliter a comparable safety profile to other available statins when used at 10 mg to 40 mg daily dose. Several cardiovascular outcome studies have confirmed the beneficial effects that had been anticipated from vascular imaging studies.

This study therefore showed that rosuvastatin 20 mg is as effective as atorvastatin 80 mg in intensive statin therapy.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Other HMG-CoA jupiher inhibitors are either natural, mevinic acid derived lovastatin, simvastatin, pravastatin or synthetic, heptenoic acid derived atorvastatin, fluvastatin. The drive towards more stringent goals for LDL-C lowering in cardiovascular risk prevention has brought high impact statin therapy into focus.

Data from Soran et al. HIV patients on highly active antiretroviral therapy are increasingly found to have hypercholesterolaemia and hypertriglyceridaemia. Unintended effects of statins in men and women in England and Wales: Long-term Intervention with Pravastatin in Ischaemic Disease.


Furthermore the combination of rosuvastatin with fenofibric acid was well tolerated and as safe as each drug used as monotherapy.

These results indicate the potential value of genetic profiling of patients to optimise statin response in a cost effective manner. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.

Its affinity for OATP-1B1 is comparable to atorvastatin but significantly greater than pravastatin or simvastatin. Eur J Cardiovasc Prev Rehabil. This is an open access article.

Drugs that antagonise organic anion transporting polypeptide 1B1. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The trial was stopped after a median follow-up of 1.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

J Am Coll Cardiol. Studies in children with heterozygous FH have shown the safety and efficacy of statins, including their effect on carotid intima thickness and arterial flow mediated dilation. In the same study rosuvastatin 20 mg achieved similar LDL-C reduction as atorvastatin 80 mg.

Author s have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material.

ApoA-1 ratio at 3 months when compared with atorvastatin 80 mg.

This article has esttudio cited by other articles in PMC. The use of rosuvastatin 40 mg with fenofibric acid or fenofibrate has not been evaluated and should therefore not be prescribed routinely. Clinical studies have demonstrated the benefits of statins in primary prevention.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Efficacy and safety of ABT- fenofibric acid in combination with rosuvastatin in patients with mixed hyperlipidaemia: White CM, et al. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. If this article contains identifiable human subject s author s were required to supply signed patient consent prior to publication.


This, coupled with its minimal CYP metabolism confers relatively better tolerability, safety and drug interaction profile. Table 6 Efficacy of statins. Rosuvastatin efficacy, safety and clinical effectiveness.

Rosuvastatin is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia. The SPARCL study showed that intensive statin therapy with atorvastatin 80 mg daily resulted in significant reduction in recurrent stroke. Study of Coronary Atheroma by Intravascular Ultrasound: Furthermore, the LDL-C of diabetic patients predicted their risk of stroke.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. When hsCRP is included in enrolment of primary prevention, rosuvastatin produced greater benefit when compared with rosuvasttatina statins.

Finally we will address its place in clinical practice. Table 5 shows drugs which can interact with rosuvastatin.

Author: admin